Forbes April 14, 2021
Amy Feldman

Sajith Wickramasekara was just 24 when he made the cut for Forbes 30 Under 30 list for his biotech R&D startup Benchling. Today, Wickramasekara joins the ranks of unicorn founders as Benchling hits a $4 billion valuation. That valuation – nearly five times what it was worth last May – comes as the company raised $200 million led by Sequoia Capital Global Equities.

“The industry tail winds have never been stronger,” Wickramasekara, now 30, told Forbes. “It’s not just happening in medicine. It’s also diagnostics, agriculture, food, consumer packaged goods. I look at it as the 4th Industrial Revolution, and I genuinely believe it is going to rewrite life as we know it.”

The new investment brings Benchling total funding...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Brazil’s plan for low-cost CAR-Ts
PacBio’s Repeat Expansion Panel, Owkin-Sanofi AI Take on Immunology, More
STAT+: Borrowing an idea from cancer immunotherapy, scientists make old-mice immune systems youthful again
Moderna gets Blackstone backing for flu vaccine R&D
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension

Share This Article